![An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment - ScienceDirect An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0278691520305299-fx1.jpg)
An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment - ScienceDirect
![Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy | European Journal of Hospital Pharmacy Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy | European Journal of Hospital Pharmacy](https://ejhp.bmj.com/content/ejhpharm/29/5/259/F1.large.jpg)
Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy | European Journal of Hospital Pharmacy
![TropicalMed | Free Full-Text | Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis TropicalMed | Free Full-Text | Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis](https://www.mdpi.com/tropicalmed/tropicalmed-05-00180/article_deploy/html/images/tropicalmed-05-00180-g003.png)
TropicalMed | Free Full-Text | Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir/Ritonavir in a Combination Therapy | Molecular Pharmaceutics
![Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial - The Lancet Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/043bdf5b-d5cf-40bc-9b89-2d1af1b83ec5/gr1.gif)
Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial - The Lancet
![Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study - The ... Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study - The ...](https://www.thelancet.com/cms/attachment/2000996624/2003695796/gr1.gif)
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study - The ...
![Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 - The Centre for Evidence-Based Medicine Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 - The Centre for Evidence-Based Medicine](https://www.cebm.net/wp-content/uploads/2020/04/lopinavir.jpg)
Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 - The Centre for Evidence-Based Medicine
![Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/ddi/2020/lopinavir-ritonavir.jpg)